HIV / AIDS

Major predictors of response were CD4+ count, suppressed viral load, and whether the participant received the Moderna or Pfizer mRNA vaccine.

Mortality rates of children with HIV may be underreported due to lack of patient follow-up and the usage of routine program data.

Cabotegravir has a target date of January 24, 2022 and would become the first long-acting HIV PrEP therapy approved.

Research suggests studies should adjust their cohort comparison group to account for demographics most represented by people living with HIV.

The Fenway Institute is hosting its upcoming Advancing Excellence in Transgender Health conference. The program will include education on transgender medical care as well as how clinicians and people within this community can interact and the former can understand the latter’s needs when it comes to preventative and acute care.

England has been meeting and exceeding its HIV diagnosis and treatment goals set by UNAIDS.

Parentless youth living on the streets had the highest rates of HIV and death, but extended-family living situations were not necessarily better than institutional care.

The importance of establishing strong relationships with patients with HIV and expert advice on building rapport.

Lifestyle management interventions that can help patients with HIV on antiretroviral therapy manage their weight.

The therapy, known as EBT-101, works by eliminating HIV-infected DNA from the genome.

To address PrEP implementation in Kenya, a team of researchers evaluated practices and contextual modifications across public HIV clinics.

Antiretroviral therapy for HIV offers a protective outcome against preterm birth for pregnant women with HIV.

The University of Miami (UM) has a community-based mobile clinic that offers PrEP counseling along with other medical services to those who might not otherwise have access to or seek clinical care.

Considerations for switching therapies used to manage patients with HIV following resistance or progression on prior treatment.

Drs Osama Hamdy and Tavell Kindall react to the association between weight gain and antiretroviral therapies used to treat HIV.

Higher HIV viral loads and additional heart disease factors increase the risk as well.

A small subset of people living with HIV (PLWH) can naturally suppress the virus without medication.

Changes in perceptions about the severity of HIV with advances in treatment and efforts to normalize living with the disease may create challenges for HIV prevention, a new study from the Netherlands suggests.

A discussion regarding the safety profile and use of bictegravir/emtricitabine/tenofovir alafenamide as treatment for HIV.

Interpretations of data supporting the use of single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide as treatment for patients with HIV and its effects on patient weight.

Islatravir exerts multiple mechanisms against HIV, demonstrates treatment effectiveness with doravirine, and is a potential weekly or monthly oral PrEP.

HIV coinfection was associated with a 3.7-fold increase in the risk of non-liver-related cancer among patients with hepatitis C virus infection, a new study found.

Optimizing delivery of HIV preexposure prophylaxis will take more than access to health care, according to a recent analysis of PrEP use behaviors among adults in an integrated health system.

Despite heightened cardiovascular disease (CVD) risk, too few get drugs at appropriate dose, researchers say.

Considerations for more widespread use of 2-drug regimens to treat patients with HIV.